Afatinib + bevacizumab combination therapy in EGFR-mutant NSCLC patients with osimertinib resistance: Protocol of an open-label, phase II, multicenter, single-arm trial.
Nobuaki KobayashHisashi HashimotoChisato KamimakiRyo NagasawaKatsushi TanakaSousuke KuboSeigo KatakuraHao ChenNobuyuki HiramaRyota UshioAyako AokiKentaro NakashimaShuhei TeranishiSaki ManabeHiroki WatanabeNobuyuki HoritaKeisuke WatanabeYu HaraMasaki YamamotoMakoto KudoHongmei PiaoTakeshi KanekoPublished in: Thoracic cancer (2020)
A previous study indicated that afatinib inhibits lung cancer cells with specific EGFR mutations more effectively than other EGFR-TKIs such as osimertinib. Therefore, we expect that combination therapy using afatinib and bevacizumab will be effective in patients previously treated with osimertinib (registration no. jRCTs031190077).
Keyphrases
- epidermal growth factor receptor
- combination therapy
- advanced non small cell lung cancer
- small cell lung cancer
- phase ii
- tyrosine kinase
- clinical trial
- open label
- end stage renal disease
- newly diagnosed
- phase iii
- ejection fraction
- chronic kidney disease
- double blind
- randomized controlled trial
- metastatic colorectal cancer
- study protocol
- brain metastases
- prognostic factors
- placebo controlled
- cross sectional
- patient reported